Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleRed Hat
CEO ReviewCompany Review

The Silicon Review Asia

Emcure led by Humayun Dhanrajgir-Finding success through innovation and technology in the field of Research and Development

The Silicon Review
September, 2019


The pharmaceutical industry is setting up new trends in the field of pharmacy and Biological sciences. The main is to discover and develop new drugs and to bring them into the market. The pharmaceutical industry aims to bring in new discoveries such as vaccines, pills, and other generic medicines. It mainly deals with medications and medical devices. They do hold patenting rights on certain medications; they also perform efficient drug testing, drug safety tests, and marketing of the newly formulated drugs. They also play a pivotal role in drug targeting and drug designing.

The pharmaceutical industry plays a vital role in the field of Life Sciences. One's such a pioneer pharmaceutical industry that is leading with an example is Emcure, headquartered at Pune in West India. The company was incorporated as Emcure Pharmaceuticals Private limited on April 16, 1981. The name of the firm embodies the purpose and core belief of the company which is to make Effective Medicine to cure patients, to lead healthier and happier lives.

The firm is ranked as the 12th largest pharmaceutical company in India in terms of market share, which is based on the domestic sales of pharmaceutical products. The firm believes that there is a competitive advantage in the domestic market lies. The company has its presence in all major therapeutic areas like blood-related, cardiology, analgesics, HIV, gynecology, nephrology, Anti-infective, vitamins, and nutrient product.

Main Objectives

The firm believes in integrity, innovation, teamwork, respecting the fellow worker, value-driven resources, and quality and most importantly they focus on its patients. These are the core values that are followed by the company.


The main vision of the firm is to emerge as a global leader, which offershigh quality and cost-effective healthcare services.

Facilities provided

Research and Development (R&D)

The in-house research and development capabilities of the company have enabled us to take innovation and technology to the next level across the world. The team is one of the cornerstones of the operations and has contributed extensively to the Indian pharmaceutical industry.

Manufacturing unit

Emcure’s manufacturing sectors are spread across 11 world-class manufacturing facilities and are ranked as the best pharmaceutical industry amongst other global leaders. The firm also has API manufacturing facilities which help in building integrity in the field of quality and cost control.

The facilities have the capability to manufacture various pharmaceutical dosage forms such as;

Solid Orals: the firm produces a wide range of solid orals like dissolvable and chewable tablets, hard and soft-shelled capsules with a controlled release and precise drug targeting.

Injectable: the company handles various packaging formats like- prefilled syringes, lyophilized as well as injectable facilities. The firm also produces cancer drugs that have complex mechanisms.

APIs: the firm manufactures distinct APIs like intermediates, iron compounds, general-purpose APIs, and cytotoxins.

Milestones achieved

Acquired Marcan pharmaceuticals Inc. in Canada, acquired Bharadwaj Pharma GMBH in Germany, expanded the company in the US to enhance manufacturing facility, Sanand Injectable facility commenced USFDA approval of Sanand and F-II, etc.

Current Research

Emcure is the premier pharmaceutical manufacturing company in India. The firm is focused on cutting-edge research. The research and development team is comprised of more than 500 scientists highly qualifies in their respective subjects and many research scholars. The team is dedicated to developing complex APIs, formulations, and biosimilars by using chemistry, biologics, analytical, regulatory, and intellectual property expertise.

The staunch behind the domicile of Emcure

Humayun Dhanrajgir, the Chairman and Director of Emcure since 2000 and a pioneer in the field of chemical engineering and pharmaceuticals. He has held several senior management positions including the position of the vice-chairman and the managing director of Glaxo India Limited. He has also held the position of the managing director of Kodak India Limited. He has also served as the president of the organization of pharmaceutical producers of India in 1992 and was also a member of the Bombay Chamber of Commerce and Industry. He is a member of Global advisory board of Asian center for corporate governance and sustainability. He is a graduate in Chemical Engineering from Loughborough University, United Kingdom.

“Wherever the art of medicine is loved, there is also a love of humanity.”


Pine Labs Reaffirms its Commitment to Indian Payments Space with Qfix Acquisition

HDFC Bank is Qfix's main distribution partner Pine Labs has announced that it has acquired Qfix, a Mumbai-based online payments startup. This acquisi...

Salesforce Expands into Thailand, Opens Office in Bangkok

Salesforce has announced permanent presence in Thailand by launching its new office in the country’s capital, Bangkok. The permanent presence wi...

GMLL is expected to soon add two more stores to its retail arm ‘Price Mantra’

Garment Mantra Lifestyle, a popular name in the Indian fashion retail segment, recently made an announcement that the company is expanding its retail ...

Tariff plans will cost higher from the next financial year as telecom companies are gearing up to increase rates

The ongoing Covid pandemic had significantly increased the number of mobile and internet users worldwide. The high amount of usage is expected to drop...